|
|
Article: DOR BioPharma Initiates New Botulinum Toxin Therapeutic Program; Complements DOR's BT-VACC ``Oral Botulinum Toxin Vaccine'' Program.
- Article from:
- Business Wire
- Article date:
- February 16, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MIAMI -- DOR BioPharma Inc. ("DOR" or the "Company") (AMEX:DOR) announced today that it has initiated a rational drug design program to identify oral, small molecule drugs to counter the deadly effects of Botulinum toxin exposure. Botulinum toxin is generally regarded as the most poisonous natural substance known to man, and has been used as a bioterror agent in the past. Currently, there are no clinically acceptable drugs that either slow or reverse the effects of Botulinum toxin.
Capitalizing on research focused on structure/function relationships of Botulinum toxin done by Lance Simpson, Ph.D., Director, Center for Research on Bioterrorism and Biodefense, ...